Bladder Neoplasms

Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Achieve Life Sciences
1 program
1
TOCOSOL PaclitaxelPhase 21 trial
Active Trials
NCT00077688CompletedEst. Sep 2007
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
1
DTA-H19Phase 1/21 trial
Active Trials
NCT00393809Completed18Est. Dec 2007
M&
Merck & Co.RAHWAY, NJ
1 program
1
SCH 721015 with SCH 209702Phase 11 trial
Active Trials
NCT00536588Completed17Est. Aug 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Achieve Life SciencesTOCOSOL Paclitaxel
Jerusalem PharmaceuticalsDTA-H19
Merck & Co.SCH 721015 with SCH 209702

Clinical Trials (3)

Total enrollment: 35 patients across 3 trials

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Start: Nov 2003Est. completion: Sep 2007
Phase 2Completed

Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer

Start: Jan 2006Est. completion: Dec 200718 patients
Phase 1/2Completed
NCT00536588Merck & Co.SCH 721015 with SCH 209702

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

Start: Sep 2006Est. completion: Aug 200917 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space